Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. · 2022
Read Immunotherapy in Lung Cancer: Current Landscape and Future Directions. by Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8864096.txt.
Description
Mamdani and co-authors survey immunotherapy for lung cancer, the top cause of cancer death. Immune checkpoint inhibitors have reshaped care for non-small cell lung cancer. They now serve as first-line treatment, as follow-up after chemoradiation, and after surgery. Small cell lung cancer gains far less from them. Predicting who will respond remains hard. Resistance, whether early or late, is common.
The review maps where checkpoint therapy now stands. It covers biomarkers that might forecast response or resistance. PD-L1 is the best known of these. The authors then examine the challenges facing this therapy. They explore targets beyond PD-1, PD-L1, and CTLA-4. CD73 earns its own section. A final thread links DNA repair defects to immunotherapy response. The piece charts both progress and gaps.
Catalog record
| CREATOR | Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |